Acerus Pharma
2486 Dunwin Drive
Mississauga
Ontario
L5L 1J9
Canada
Tel: 416-679-0771
Website: http://www.aceruspharma.com/
154 articles about Acerus Pharma
-
Acerus to Report 2018 Financial Results and Host Investor Call
2/26/2019
Acerus Pharmaceuticals Corporation will announce financial results for the three and twelve month periods ending December 31, 2018 on Tuesday, March 05, 2019 before market opens.
-
Acerus Receives Notice of Deficiency – Withdrawal Letter from Health Canada Regarding Gynoflor™ Application
1/25/2019
Acerus Pharmaceuticals Corporation is today advising that it has received a Notice of Deficiency-Withdrawal Letter (“Notice”) for its GynoflorTM New Drug Submission.
-
Acerus Announces Reporting of Anticipated Shortage of ESTRACE®
1/11/2019
Acerus Pharmaceuticals Corporation is today advising that it has reported an anticipated shortage of certain doses of ESTRACE® on the Drug Shortages Canada website in relation to supply issues arising from the Company’s contract manufacturer.
-
Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
12/11/2018
The THC trial, previously announced on October 24, 2018, involved 12 overnight-fasting, healthy subjects with prior cannabis experience.
-
Acerus Provides Update on Continuing Commercial and R&D Achievements for NATESTO®
11/26/2018
Acerus Pharmaceuticals Corporation is today providing an update on a number of significant operational and research achievements related to NATESTO®, one of the Company’s core strategic assets.
-
Acerus Reports Third Quarter 2018 Financial Results
11/6/2018
Increased product revenue by 16% to $1.6 million versus $1.4 million in the same three-month period in the prior year.
-
Acerus Announces Expansion of NATESTO® Agreement with medac and the Submission of NATESTO® Dossier in Europe
10/31/2018
--Amended Agreement Now Covers the Current EU Member States (including the UK) plus Eight Other Countries--
-
Acerus Announces Executive Leadership Changes in Corporate Finance
10/30/2018
– Robert Motz joins Acerus as Chief Financial Officer –
-
Acerus Announces Closing of US$11 Million Term Loan Credit Facility
10/12/2018
Acerus Pharma (the “Company” or “Acerus”) (TSX:ASP) today announced that it has entered into a senior secured term loan credit facility with SWK Funding LLC (“SWK”) for up to US$11 million (the “New Facility”).
-
Acerus Announces Publication of Manuscript Reporting Early Data from Partner-Sponsored Natesto® Spermatogenesis Study
9/17/2018
Early Data Suggests Sperm Concentration, Motility, and Total Motile Sperm Count Remain Within Normal Ranges in Hypogonadal Men Taking Natesto®
-
Acerus Reports Second Quarter 2018 Financial Results
8/13/2018
Acerus Pharmaceuticals Corporation reported its financial results for the three months and six months ended June 30, 2018. Unless otherwise noted, all amounts are in U.S. dollars.
-
Acerus Announces Approval of NATESTO® in South Korea
6/14/2018
This approval marks an important milestone in establishing NATESTO® globally as this is the first regulatory approval outside of North America
-
Acerus Announces Resignation of Director
6/6/2018
Acerus Pharmaceuticals Corporation announced that Mr. Luc Mainville has stepped down as a director of the company.
-
Acerus Acquires Canadian Rights to Novel Pain Relief Product for Gynecological Procedures from Pharmanest
5/29/2018
Acerus Pharmaceuticals Corporation today announced that it has entered into an exclusive agreement to commercialize Pharmanest AB (“Pharmanest”) Short Acting Lidocaine product (“SHACT”), a novel pain relief drug device combination in Canada.
-
Acerus Reports First Quarter 2018 Financial Results
5/15/2018
Product revenues increased 60% to $1.6 million versus $1.0 million in the same prior year period
-
Acerus Announces Licensing of NATESTO® in 19 Central and Latin American Countries
4/13/2018
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced the signing of an agreement granting Producto Científicos, S.A. de C.V (“Carnot Laboratorios”) the exclusive right to market NATESTO® in 19 Central and Latin American countries
-
Acerus Announces Settlement of Melnyk Litigation
4/10/2018
Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that the Company and certain of its present and former directors and officers have reached a settlement with Eugene Melnyk
-
Acerus Announces Launch of URIVARX® in Canada
4/9/2018
Acerus had previously planned for the Canadian launch of URIVARX® in the second half of 2018, but the Company has arranged for the product to be available in Canada via the Innovus supply chain.
-
Acerus Reports Fourth Quarter and Full Year 2017 Financial Results
3/21/2018
Acerus Pharmaceuticals Corporation reported its financial results for the three and twelve-month period ended December 31, 2017.
-
Acerus Pharma’s NATESTO to Be Listed for Public Reimbursement in Quebec, Building on Strong 28% Increase in Natesto’s Canadian Prescriptions in Q4 2017
2/2/2018
Acerus Pharma announced that it has received notice from Quebec’s National Institute for Excellence in Health and Social Services (INESSS) of a positive recommendation to the Health Minister for the inclusion of NATESTO® on the list of medications of the Régie de l’assurance maladie du Québec.